Literature DB >> 11754378

Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature.

May Lynn Quan1, Janice L Pasieka, Otto Rorstad.   

Abstract

BACKGROUND: The effects of subclinical hyperthyroidism on bone mineral density (BMD) induced by suppressive thyroxine therapy in patients with well-differentiated thyroid cancer (WDTC) remains unclear. An overview of the current literature was undertaken to evaluate studies to date.
METHODS: A systematic medline search yielded a total of 11 studies appropriate for review which included premenopausal women, postmenopausal women, and men on suppressive thyroxine post thyroidectomy for WDTC. Main outcome measures were bone mineral density and bone turnover markers.
CONCLUSIONS: Although studies were limited by small numbers and varying degrees of control for confounding variables, results suggested no significant change in bone mineral density for premenopausal women or men. Findings for postmenopausal women remain unclear with two of the best controlled studies reporting opposing results. Further studies for this population are recommended to help guide clinical practice. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11754378     DOI: 10.1002/jso.10043

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  17 in total

Review 1.  Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients.

Authors:  E N Klein Hesselink; T P Links
Journal:  Eur Thyroid J       Date:  2015-06-11

Review 2.  Thyroid hormone therapy in differentiated thyroid cancer.

Authors:  Giorgio Grani; Valeria Ramundo; Antonella Verrienti; Marialuisa Sponziello; Cosimo Durante
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

3.  Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine?

Authors:  Graham R Williams
Journal:  J Endocrinol Invest       Date:  2014-06-18       Impact factor: 4.256

Review 4.  Role of Thyroid Hormones in Skeletal Development and Bone Maintenance.

Authors:  J H Duncan Bassett; Graham R Williams
Journal:  Endocr Rev       Date:  2016-02-10       Impact factor: 19.871

5.  The influence of thyroid dysfunction on bone metabolism.

Authors:  Dominika Tuchendler; Marek Bolanowski
Journal:  Thyroid Res       Date:  2014-12-20

6.  Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer.

Authors:  Mi Young Lee; Jae Hyun Park; Keum Seok Bae; Yong Gwan Jee; An Na Ko; Yong Jea Han; Jang Yel Shin; Jung Soo Lim; Choon Hee Chung; Seong Joon Kang
Journal:  Ann Surg Treat Res       Date:  2014-01-22       Impact factor: 1.859

Review 7.  Follicular thyroid carcinoma.

Authors:  Philip I Haigh
Journal:  Curr Treat Options Oncol       Date:  2002-08

Review 8.  Thyrotropin, Hyperthyroidism, and Bone Mass.

Authors:  Se-Min Kim; Vitaly Ryu; Sari Miyashita; Funda Korkmaz; Daria Lizneva; Sakshi Gera; Rauf Latif; Terry F Davies; Jameel Iqbal; Tony Yuen; Mone Zaidi
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

9.  Metabolic and clinical consequences of hyperthyroidism on bone density.

Authors:  Jagoda Gorka; Regina M Taylor-Gjevre; Terra Arnason
Journal:  Int J Endocrinol       Date:  2013-07-22       Impact factor: 3.257

Review 10.  Thyroid diseases and bone health.

Authors:  G R Williams; J H D Bassett
Journal:  J Endocrinol Invest       Date:  2017-08-29       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.